We are live on
!
Find out more
Temasek Holdings Portfolio holdings
AUM
$30.5B
1-Year Est. Return
13.98%
This Fund
S&P 500
This Quarter
Est. Return
+13.5%
1 Year Est. Return
+13.98%
3 Year Est. Return
+73.05%
5 Year Est. Return
+59.18%
10 Year Est. Return
+409.11%
AUM
$15.5B
AUM Growth
+$2.1B
(+16%)
Cap. Flow
+$472M
Cap. Flow
% of AUM
3.04%
Top 10 Holdings %
Top 10 Hldgs %
80.2%
Holding
61
New
21
Increased
4
Reduced
6
Closed
2
Top Buys
| 1 |
NFX
Newfield Exploration
NFX
|
+$208M |
| 2 |
GRA
W.R. Grace & Co.
GRA
|
+$153M |
| 3 |
RDS.B
Royal Dutch Shell PLC ADS Class B
RDS.B
|
+$114M |
| 4 |
Broadcom
AVGO
|
+$87.2M |
| 5 |
KREF
KKR Real Estate Finance Trust
KREF
|
+$53.6M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
+$221M |
| 2 |
Dell
DELL
|
+$77.3M |
| 3 |
ATH
Athene Holding Ltd. Class A Common Shares
ATH
|
+$74.4M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$68.1M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$18.7M |
Sector Composition
| 1 | Consumer Discretionary | 38.44% |
| 2 | Industrials | 25.96% |
| 3 | Healthcare | 11.91% |
| 4 | Communication Services | 6.21% |
| 5 | Materials | 5.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VNET
26
VNET Group
VNET
$2.2B
| $54.1M | 0.35% |
10,778,004
| – | – |
|
|
KREF
27
KKR Real Estate Finance Trust
KREF
$489M
| $52.4M | 0.34% |
+2,439,024
| New | +$53.6M |
|
28
Illumina
ILMN
$28.8B
| $48.1M | 0.31% |
285,024
| – | – |
|
|
ATH
29
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $42.8M | 0.28% |
862,204
-1,450,490
| -63% | -$74.4M |
|
|
NETS
30
DELISTED
Netshoes (Cayman) Limited
NETS
| $39.4M | 0.25% |
+2,071,127
| New | +$37.4M |
|
31
Mastercard
MA
$487B
| $32.4M | 0.21% |
267,006
| – | – |
|
|
EMWP
32
DELISTED
Eros Media World PLC
EMWP
| $31.5M | 0.2% |
137,766
| – | – |
|
33
State Street SPDR S&P Regional Banking ETF
KRE
$5.05B
| $28.3M | 0.18% |
+515,700
| New | +$27.7M |
|
|
JUNO
34
DELISTED
Juno Therapeutics, Inc.
JUNO
| $27.4M | 0.18% |
915,750
| – | – |
|
|
CELG
35
DELISTED
Celgene Corp
CELG
| $26.8M | 0.17% |
+206,187
| New | +$25.3M |
|
36
Amgen
AMGN
$201B
| $26.1M | 0.17% |
+151,310
| New | +$24.6M |
|
37
Biogen
BIIB
$30.8B
| $25.8M | 0.17% |
+95,226
| New | +$25.2M |
|
|
MON
38
DELISTED
Monsanto Co
MON
| $25.5M | 0.16% |
+215,534
| New | +$25.2M |
|
39
Incyte
INCY
$23.3B
| $25.3M | 0.16% |
+201,304
| New | +$25.6M |
|
40
ICICI Bank
IBN
$106B
| $25.2M | 0.16% |
2,808,987
-1
| -0% | -$8 |
|
41
Vertex Pharmaceuticals
VRTX
$123B
| $25M | 0.16% |
+194,199
| New | +$23.4M |
|
42
JPMorgan Chase
JPM
$912B
| $24.2M | 0.16% |
+264,337
| New | +$22.8M |
|
43
Bank of America
BAC
$432B
| $19.4M | 0.12% |
+798,123
| New | +$18.6M |
|
|
ONC
44
BeOne Medicines Ltd
ONC
$32.9B
| $17.1M | 0.11% |
380,000
| – | – |
|
45
Wells Fargo
WFC
$267B
| $14.4M | 0.09% |
+260,364
| New | +$13.9M |
|
46
Intellia Therapeutics
NTLA
$1.66B
| $12.6M | 0.08% |
790,527
| – | – |
|
47
AC Immune
ACIU
$222M
| $11.8M | 0.08% |
1,337,500
| – | – |
|
|
AMRS
48
DELISTED
Amyris Inc.
AMRS
| $10.5M | 0.07% |
3,302,585
-152,629
| -4% | -$824K |
|
49
Morgan Stanley
MS
$343B
| $4.82M | 0.03% |
+108,260
| New | +$4.67M |
|
50
Goldman Sachs
GS
$323B
| $4.51M | 0.03% |
+20,337
| New | +$4.52M |
|
Similar funds
Temasek Holdings's Q2 2017 Portfolio in Review
As of Q2 2017, Temasek Holdings held 61 positions worth $15.5B, up 16% from $13.4B the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Temasek Holdings deployed $472M of net new capital in Q2 2017, opening 21 new positions and adding to 4 existing holdings. Its largest new stake was Newfield Exploration: 6,326,046 shares worth $180M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, up from 34% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was Gilead Sciences, an estimated $221M trimmed.
- Temasek Holdings's largest Q2 2017 buy was Newfield Exploration: 6,326,046 shares worth $180M.
- Temasek Holdings added most to Royal Dutch Shell PLC ADS Class B in Q2 2017, an estimated $114M increase.
- Temasek Holdings's biggest Q2 2017 reduction was Gilead Sciences, cutting an estimated $221M.
- Temasek Holdings fully exited Dell in Q2 2017, selling an estimated $77.3M.
- Temasek Holdings's ten largest holdings make up 80% of its $15.5B portfolio in Q2 2017.
- Temasek Holdings opened 21 new positions and closed 2 in Q2 2017.
- Temasek Holdings's portfolio value rose 16% quarter-over-quarter to $15.5B.
Based on Temasek Holdings's 13F filing for Q2 2017, filed 14 Aug 2017.